UK | pharmaphorum

UK

News

Genomics England will move HQ to Canary Wharf's new bioclust...

Canary Wharf's bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development.

News

MHRA gives Alnylam 'innovation passport' for hypertension dr...

The UK medicines regulator has awarded Alnylam's RNAi-based therapy zilebesiran for hypertension an 'innovation passport', a

Patients

Representation in UK pharma: A progress report

Pharma understands that building equitable health services starts with building equitable institutions.

News

UK grants early access to Argenx' efgartigimod for myastheni...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG) to get early access to Argenx' efgartigimod while it reviews the marketing applic

News

GSK said to be close to finding partner for science cluster ...

GlaxoSmithKline is reportedly close to finding a development partner for a major new investment project in the UK that will see a new bioscience cluster built near its research centre in St

News

group of chemical scientists working at the laboratory.

EU imposes Horizon funding block on UK scientists

UK scientists are being denied from joining the €95 billion Horizon research funding programme as a dispute over the trade border in Northern Ireland gets increasingly acrimonious.

Genomics England will move HQ to Canary Wharf's new bioclust...

MHRA gives Alnylam 'innovation passport' for hypertension dr...

Representation in UK pharma: A progress report

UK grants early access to Argenx' efgartigimod for myastheni...

GSK said to be close to finding partner for science cluster ...

EU imposes Horizon funding block on UK scientists

As patents expire, fampridine is cleared for NHS use in MS

Discover a new era of healthcare panel engagement: Grounded ...

UK

Editor's Picks